Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Byondis B.V.
Memorial Sloan Kettering Cancer Center
Celgene
Dana-Farber Cancer Institute
Cedars-Sinai Medical Center
Pfizer
OrphAI Therapeutics
Masonic Cancer Center, University of Minnesota
I-Mab Biopharma US Limited
Pfizer
Celgene
Fate Therapeutics
Fate Therapeutics
Weill Medical College of Cornell University
M.D. Anderson Cancer Center
The Lymphoma Academic Research Organisation
National Institutes of Health Clinical Center (CC)
Cogent Biosciences, Inc.
Curis, Inc.
University of California, San Francisco
M.D. Anderson Cancer Center
University of California, San Francisco
AIDS Malignancy Consortium
Cogent Biosciences, Inc.
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Swiss Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Milton S. Hershey Medical Center
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center
University of Kentucky
SCRI Development Innovations, LLC
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Georgetown University
University of California, San Francisco
Seagen Inc.
Emory University
National Cancer Institute (NCI)
University of Alabama at Birmingham
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
Memorial Sloan Kettering Cancer Center
Jonsson Comprehensive Cancer Center